Scott Tagawa, MD, MS, FACP, and fellow researchers carried out a phase 1/2 trial investigating the combination of 225Ac-J591 with 177Lu-PSMA-I&T (aka PNT2002). The study’s results will be presented at the American Society of Clinical Oncology 2023 Annual Meeting. Eligible patients had progressive metastatic castration-resistant prostate cancer (mCRPC), 2 or more prior androgen receptor pathway inhibitors, prior chemotherapy (or unfit/refuse), and 1 or more lesions with a standardized uptake value greater than liver uptake. ...
Advertisement
Advertisement
Latest News
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
PROPELLER: Assessing a Novel Imaging Agent in Patients With Intermediate-, High-Risk Prostate Cancer
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.
An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Results of the STARTAR phase 2 trial on salvage RT plus apalutamide and docetaxel were presented at the 2023 ASCO meeting.
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
KEYNOTE-361: Complete Response Outcomes With First-line Pembrolizumab or Platinum-Based Chemotherapy
A post-hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
The FDA has approved the combination treatment of olaparib with abiraterone and prednisone for BRCA-mutated mCRPC.
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
Drs. Koshkin, Basu break down treatment considerations based on ctDNA status after radical cystectomy, among other factors.
Drs. Koshkin and Basu discuss how ctDNA are being evaluated for disease recurrence, response monitoring in advanced UC.
Questions from the surveys were rated as relevant or nonrelevant by patients with RCC.
Advertisement
Advertisement
Editorial Advisory Board
Brian Rini, MD, FASCOEditor | Chief of Clinical Trials at Vanderbilt-Ingram Cancer Center
Thomas Powles, MBBS, MRCP, MDEditor | Director, Barts Cancer Centre at St. Bartholomew's Hospital
Catherine H. Marshall, MD, MPHEditor | Assistant Professor of Oncology at the Johns Hopkins University School of Medicine
Jérémie Calais, MD, MScEditor | Director of the Theranostics and Clinical Research Programs at the University of California, Los Angeles
Akhil Abraham Saji, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
David Ambinder, MDAssociate Editor | Urology Resident at New York Medical College/Westchester Medical Center
Expert Interviews
Dr. Siefker-Radtke shares the novel targeted therapies for bladder cancer and how they are assessed in combinations.
Dr. Msaouel shares his journey to becoming a world expert in RMC and the clinical trial work he led to improve outcomes.
Katherine Virgo, PhD, MBA, provided insight into ASCO's updated guideline for the management of metastatic prostate cancer.
Michigan Urological Surgery and Improvement Collaborative is an effort to improve patient lives through high-quality care.
A recent study examined safety and efficacy from the ARASENS trial for certain subgroups by disease volume and risk.
Dr. A. Ari Hakimi discusses how cytoreductive nephrectomy has evolved and is being used in today’s mRCC treatment paradigm.
Knowledge Hubs
Curated clinical content based on conditions, therapies, and technologies
GU Oncology Now delivers the latest news in clinical trials, conference coverage, and more, highlighting advancements in genitourinary oncology treatments and tech.
Get research and breaking news straight to your inbox.
The Uromigos
Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD
Conference Coverage
Live meeting highlights
Results from the CHAARTED trial demonstrated that ADT and docetaxel improves OS and QOL at 12 months compared with ADT alone.
A post hoc analysis of the IMvigor130 trial examined OS outcomes during first-line induction for patients with mUC.
PROPELLER: Assessing a Novel Imaging Agent in Patients With Intermediate-, High-Risk Prostate Cancer
64Cu-SAR-bisPSMA may be safe and effective for detecting PSMA-expressing lesions, and 200MBq may be the optimal dose.An observational study sought to determine variation in recurrence after TURBT between sites taking part in the RESECT study.
Video Insights
Clinical discussions with experts in the field
